At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
MPER-656 Liposome Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 2, 2019·Updated Sep 25, 2025
In Brief
A Phase 1 clinical trial evaluating MPER-656 Liposome Vaccine and Placebo for MPER-656 Liposome Vaccine for HIV Infections. Completed, enrolled 24 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartAug 2019
Primary CompletionFeb 2021
Study CompletionMay 2021
TodayJul 2026
First PostedMay 2, 2019
Enrollment StartAug 26, 2019
Primary CompletionFeb 5, 2021
Study CompletionMay 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.2 years ago
Interventions
MPER-656 Liposome Vaccinebiological
Administered by intramuscular injection
Placebo for MPER-656 Liposome Vaccinebiological
Administered by intramuscular injection